LAS VEGAS--(BUSINESS WIRE)--Samaritan Pharmaceuticals (OTCBB:SPHC) (http://www.samaritanpharma.com), a biopharmaceutical company committed to commercializing new innovative therapeutic drugs, announced that it has filed an IND (Investigational New Drug) application for SP-6310 in the treatment of HIV-infected patients with abnormal cortisol levels. Following discussions and protocol agreement with U.S. Food and Drug Administration (FDA), Samaritan will conduct an 8-week Phase II clinical study with SP-6310 in HIV-infected patients with abnormal cortisol levels while on antiretroviral therapy. Samaritan expects that the results of this study will confirm the positive results found in a previously conducted Phase I/II.
